Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $264,110
CYTK•Insider sale details
- Fady Ibraham Malik, EVP Research & Development at Cytokinetics, sold 3,500 common shares on Sep. 8, 2026 at $75.46 per share.
- The sale followed the exercise of 3,500 non-qualified stock options at $7.80 per share.
- Direct common stock holdings fell to 153,902 shares.
- Non-qualified stock options held declined to 26,886, with an exercise price of $7.80.
